Essayer OR - Gratuit
If India Is The Fastest-Growing Big Economy, Why Invest Elsewhere?
Mint Mumbai
|August 14, 2025
No market performs consistently and one should diversify asset holdings across multiple markets
As I write this column, I look at how the Indian rupee has done since the beginning of 2025. At first glance, it appears that nothing too out of the ordinary happened, with the rupee depreciating a gentle 2.2% against the US dollar. But change the reference currency and it is down a whopping 15% versus the euro and the Swiss franc and 9% versus the British pound.
With all the ups and downs of student visas to the US, if you were now thinking of sending your daughter to Europe to study, the bill has suddenly shot up by 15% in a matter of months.
Go back over the years and the picture begins to look even worse. When I started working in the 1980s, the US dollar exchanged hands at 12. Today, it has depreciated by almost 90% in the course of less than a career. That is a straight hit to your portfolio, one that you often do not think about.
In all financial planning, you target long-term goals, typically 10, 20 or 30 years hence: for retirement, children's education, etc. You simply cannot afford to forget the fact that the rupee depreciates over time.
If anything, over time many more Indians want to holiday abroad and want themselves or their children to study overseas. Several people have kids living elsewhere and want to spend some time with them after retirement.
Cette histoire est tirée de l'édition August 14, 2025 de Mint Mumbai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

